Janux Therapeutics has initiated Phase 1b expansion studies of JANX007 in taxane-naïve metastatic castration-resistant prostate cancer patients, marking progression to earlier treatment lines.
The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.